Clinical Trials Logo

Clinical Trial Summary

Objectives: To evaluate the non-inferiority in the intraocular pressure decrease of the preservative-free ophthalmic solution PRO-122, manufactured by Laboratorios Sophia S.A. de C.V., versus concomitant therapy in subjects with uncontrolled primary open-angle glaucoma and/or IOP. Hypothesis: The mean (average) value of the IOP final absolute reduction in the experimental group (PRO-122) is not lower, considering a lower limit of 1 mmHg, compared to the IOP mean absolute reduction of the standard group (concomitant therapy). Methodology: A non-inferiority, phase III, double-blind, randomized, controlled, parallel, clinical trial


Clinical Trial Description

Number of patients: 51 subjects divided into 3 groups (17 subjects per group) Diagnosis and main inclusion criterion: Diagnosis: Primary open-angle glaucoma or ocular hypertension Main criteria: - Patients of either sex - Average intraocular pressure (IOP) ≤ 36 mm/Hg - Previous management with ocular hypotensive medications ≥ 2 months, without achieving control (target IOP) - Age ≥ 18 years - Informed consent Test product, dosage and route of administration: - PRO-122. Preservative-free ophthalmic solution of timolol 0.5% / brimonidine 0.2% / dorzolamide 2% Manufactured by Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico. + Placebo + Placebo - Dosage: 1 drop every 12 hours - Route of administration: ophthalmic Treatment duration: 90 days Evaluation criteria: Efficiency (non-inferiority): - IOP decrease Safety: - Best corrected visual acuity - Cup-to-disc ratio - Visual fields determined by computerized perimetry - Central corneal thickness determined by pachymetry - Ocular surface integrity, including: - Conjunctival hyperemia - Chemosis - Fluorescein staining - Density of goblet cells - Adverse events Tolerability: - Ocular comfort index Statistical methodology: The data will be expressed with measures of central tendency: mean and standard deviation for quantitative variables. The qualitative variables will be presented in frequencies and percentages. Statistical analysis will be done by means of a Kruskal-Wallis test for quantitative variables. The difference between qualitative variables will be analyzed using an square chi An alpha ≤ 0.05 would be considered as significant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03193333
Study type Interventional
Source Laboratorios Sophia S.A de C.V.
Contact Ricardo Llamas, PhD
Phone (33)30014200
Email ricardo.llamas@sophia.com.mx
Status Recruiting
Phase Phase 3
Start date November 6, 2017
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT01841437 - Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry N/A
Completed NCT01410188 - Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension Phase 1/Phase 2
Completed NCT02077231 - Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients N/A
Recruiting NCT05557058 - GORE Glaucoma Drainage Implant Clinical Study N/A
Not yet recruiting NCT03924544 - Decorin in Sub Scleral Trabeculectomy Phase 1
Active, not recruiting NCT03673644 - Impact of Glaucoma and Visual Field Loss on Life Space
Completed NCT03365778 - Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment N/A
Completed NCT01915940 - Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Phase 2
Completed NCT03889652 - Optical Coherence Tomography of Nerve Fiber Layer and Ganglion Cell Complex After Cataract Extraction
Terminated NCT03273907 - Post Approval Study of the CyPass System N/A
Recruiting NCT03921931 - Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study N/A
Not yet recruiting NCT04609345 - Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
Recruiting NCT05264818 - Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
Completed NCT04333433 - PRESERFLO® MicroShunt Extension Study
Enrolling by invitation NCT02144103 - Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration Phase 1/Phase 2
Completed NCT01281020 - Adherence With Fixed Versus Unfixed Glaucoma Therapy
Recruiting NCT04891588 - Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD N/A
Completed NCT03145129 - PAIR Study-PAP And IOP Relationship: Study 2
Completed NCT03104621 - Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Phase 4
Completed NCT01528111 - Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Phase 1/Phase 2